TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00644618
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
Study: NCT00046163
Drug: midodrine hydrochloride (ProAmatine®)
Normalized name: midodrine hydrochloride Oral Tablet [Proamatine]
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03251859
Drug: Ticagrelor 90 mg
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 90 mg twice daily
Study: NCT03251859
Drug: Ticagrelor 60 mg
Normalized name: ticagrelor 60 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 60 mg daily
Study: NCT04462809
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib 1 mg a day (PO) (or 0.75 mg a day) for 2 years, started between 6 to 8 weeks after the end of chemotherapy discontinuation.~Talazoparib will be given for up to 2 years, or less length of time in the case of disease progression,.~unacceptable toxicity despite adequate management,patient decides to withdraw from the study, or general or specific changes in the patient's condition render the patient unacceptable for further treatment.
Study: NCT03297489
Drug: Fluorescein Sodium Injection
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00787930
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, 250mg-3000mg
Study: NCT01992614
Drug: PF-06678552 or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
Study: NCT00777179
Drug: Vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, oral, daily
Study: NCT03416231
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib, at a dose of 250 mg daily,Treatment was continued until disease progression.
Study: NCT03416231
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel, at a dose of 75mg/m2 on days 1 and 22, repeat every 4 weeks for 4\~6 cycles.
Study: NCT01412229
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
Study: NCT01412229
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
Study: NCT01412229
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
Study: NCT00787787
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03103893
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: topical formulation
Study: NCT04671082
Drug: Tolperisone Hydrochloride
Normalized name: Tolperisone hydrochloride
DrugBank: Tolperisone (DB06264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TID
Study: NCT01445522
Drug: ABT-888
Normalized name: ABT-925
DrugBank: ABT-288 (DB15192)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006799
Drug: megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04492709
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subjects will receive single doses of midazolam solution 2 mg/mL orally on Day 1 alone in Treatment Period 1 and on Day 7 co-administered with oral AZD5718 tablet in Treatment Period 3.
Study: NCT02256267
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03594149
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 500 mg/d p.o.
Study: NCT01352741
Drug: Tapentadol Prolonged Release
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 - 500 mg per day orally twice daily for a maximum of 12 weeks
Study: NCT01352741
Drug: Tapentadol Prolonged Release with Pregabalin
Normalized name: tapentadol Extended Release Oral Tablet
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tapentadol Prolonged Release 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
Study: NCT01352741
Drug: Tapentadol Prolonged Release open label maintenance
Normalized name: tapentadol Extended Release Oral Tablet
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily
Study: NCT01587638
Drug: carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: carvedilol immediate-release (IR) and carvedilol controlled-release (CR)
Study: NCT00322595
Drug: Quetiapine fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00322595
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00493636
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
Study: NCT00493636
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
Study: NCT02282371
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02630420
Drug: cetuximab and savolitinib
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosage of combined cetuximab and savolitinib will be determine in Part 1 of the study, Part 2 will use the findings of Part 1 to further assess safety and to assess efficacy of this drug combination.
Study: NCT01741532
Drug: Deferiprone oral solution
Normalized name: deferiprone Oral Solution
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone 80 mg/mL oral solution will be administered twice daily (b.i.d.) for 18 months. An initial dose of 5 mg/kg b.i.d. will be administered for 6 weeks. The dose will then be escalated to 10 mg/kg b.i.d. and finally to 15 mg/kg b.i.d.
Study: NCT02463032
Drug: GTx-024
Normalized name: toremifene
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To determine whether either or both doses result in an acceptable clinical benefit rate.
Study: NCT00572611
Drug: [14C]-bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Single oral dose of 20 mg \[14C\]-bilastine. 1 capsule. 1 day dosing only
Study: NCT02741570
Drug: Cetuximab/Erbitux
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02741570
Drug: Cisplatin/Platinol
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02741570
Drug: Carboplatin/Paraplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01155921
Drug: Risperidone Orally Disintegrating Tablets
Normalized name: Risperidone Orally Disintegrating Tablets
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
Study: NCT00000357
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01151605
Drug: Dextrose infusion
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 12.5% will be infused at a rate to maintain blood glucose level 80-120mg/dl
Study: NCT00859339
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine ( 1000 mg/m2) IV days 1 and 8
Study: NCT00859339
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (70 mg/m2) IV day 1
Study: NCT00859339
Drug: Sunitinib Malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib malate (37.5 mg) oral daily for days 1-14
Study: NCT01740089
Drug: Algeron
Normalized name: Algeron
DrugBank: Cepeginterferon alfa-2B (DB12814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
Study: NCT01740089
Drug: PegIntron
Normalized name: PegIntron
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 μg/kg/week subcutaneously in combination with ribavirin
Study: NCT01740089
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800-1400 mg/day orally
Study: NCT01338077
Drug: Sodium alginate
Normalized name: Sodium Alginate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral suspension, 50 mg/ml, 20 ml three times daily, 4 weeks
Study: NCT01338077
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg capsule, 1 capsule once daily, 4 weeks
Study: NCT03369041
Drug: Irinotecan-Eluting Beads
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03703310
Drug: Patidegib Topical Gel, 2%
DrugBank: Patidegib (DB12655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patidegib Topical Gel, 2%
Study: NCT03703310
Drug: Patidegib Topical Gel, Vehicle
DrugBank: Patidegib (DB12655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patidegib Topical Gel, Vehicle
Study: NCT02036164
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/m2 i.v.
Study: NCT02036164
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg m2 i.v.
Study: NCT02036164
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 i.v.
Study: NCT03698045
Drug: PRO-143 Ophthalmic Solution
Normalized name: dipivefrin hydrochloride Ophthalmic Solution [AK-Pro]
DrugBank: Dipivefrin (DB00449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.
Study: NCT00303446
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg/day
Study: NCT00979368
Drug: BMS-816336
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days
Study: NCT00979368
Drug: BMS-816336
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days
Study: NCT00979368
Drug: BMS-816336
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days
Study: NCT00979368
Drug: BMS-816336
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days
Study: NCT00979368
Drug: BMS-816336
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days
Study: NCT01777555
Drug: CVT-301
Normalized name: CVT-6883
DrugBank: CVT-6883 (DB05936)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03415698
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF will be administered at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days. four such cycles will be administered at three monthly intervals.
Study: NCT00593853
Drug: Methylphenidate Hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
Study: NCT00750529
Drug: Galantamine and Donepezil
Normalized name: donepezil and memantine
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the analysis of two inhibitors of Ach-E : galantamine and donézepil in over 65 years old patients suffering from Alzheimer's disease (MMSE between 20 and 26) without Alzheimer's medication
Study: NCT05340634
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 4 mg once a day
Study: NCT00642174
Drug: prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.
Study: NCT00642174
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.
Study: NCT02068846
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.
Study: NCT04371796
Drug: Sintilimab injection
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab injection 200mg, 2cycles of treatment before surgery
Study: NCT02210663
Drug: veliparib (ABT-888)
Normalized name: ABT-925
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.
Study: NCT02286934
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Day 1 to 3 : Carvedilol 12.5 mg qd~* Day 4 to 8 : Carvedilol 25 mg qd~* Day 9 to 11 : Carvedilol 12.5 mg qd
Study: NCT00081315
Drug: Amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04205851
Drug: KIN-1901
Normalized name: KIN-3248
DrugBank: KIN-3248 (DB17587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KIN-1901 is a fully human monoclonal antibody (mAb).
Study: NCT03411252
Drug: Mirabegron 50 MG
Normalized name: mirabegron 50 MG
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myrbetriq (Mirabegron) tablet
Study: NCT01967823
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days -7 to -3: Fludarabine 25 mg /m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
Study: NCT01967823
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aldesleukin 720,000 IU/kg intravenously (IV) (based on total body weight) over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
Study: NCT03690739
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration according to investigator's discretion
Study: NCT03690739
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration according to investigator's discretion
Study: NCT00525733
Drug: darunavir 800 mg
Normalized name: darunavir 800 MG
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
Study: NCT03690739
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administration according to investigator's discretion
Study: NCT03690739
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administration according to investigator's discretion
Study: NCT03690739
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administration 1.1 mg/m² q21
Study: NCT03690739
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration according to investigator's discretion
Study: NCT03927313
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For both experimental arms: 1.2g linezolid 28 days, followed by 600mg linezolid for 28 days
Study: NCT03927313
Drug: High dose rifampicin
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For both experimental arms: additional 25mg/kg (making a total of 35mg/kg) rifampicin, for the first 56 days of treatment
Study: NCT03927313
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For only one of the experimental arms: 1000mg of aspirin daily for 56 days.
Study: NCT03927313
Drug: Standard of Care anti-tuberculous therapy
Normalized name: Anti-CD5 CAR T-cell therapy
DrugBank: Anti-CD5 CAR T-cell therapy (DB17279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.
Study: NCT01710228
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS
Study: NCT03927313
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone according to doses of Thwaites criteria for the first 8 weeks of anti-tuberculous treatment. Doses differ according to participants Medical Research Council (MRC) grade. Given orally if participant can swallow and intravenously if they cannot.
Study: NCT02442791
Drug: Byetta (Lilly, Exenatide)
Normalized name: Byetta
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See description of Arms
Study: NCT01364805
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants receive dexamethasone 10 mg as pretreatment antiemetic; may be given ondansetron, granisetron, or dolasetron, per oncologist. Gemcitibane 1,000mg/m2 IV over 30 minutes Q 21 days. Cycle of treatment: infusions once weekly for 2 consecutive weeks followed by 1 week of rest to continue treatment schedule until they experience disease progression or unacceptable toxicity. CR, PR or SD: treatment will be continued for at least 6 cycles. Discontinuation of therapy may be considered if agreed upon by the participant and oncologist. Dose Modifications: If the patient experiences more than one toxicity, each requiring a dose reduction, follow the guidelines that give the largest dose reduction for the drug. Subsequent doses can be adjusted to as low as 500 mg/m2 for gemcitabine.
Study: NCT05877040
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Open label proof-of-concept study with intravenous Rituximab, given at the dose of 1g in one day, followed by the same dose after two weeks
Study: NCT00951522
Drug: GS-9411
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhaled GS-9411 dissolved in sterile saline
Study: NCT00827281
Drug: D-cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dosage prior to sessions 3, 4 \& 5
Study: NCT00535158
Drug: Ergocalciferol (Vitamin D 2)
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50,000units once weekly for 8 weeks then every other week for 4 weeks
Study: NCT01689623
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=40, form=tablet, route=oral. Atorvastatin will be administered as a single oral 40-mg dose on Day 1 and Day 13.
Study: NCT00369226
Drug: Bortezomib (Velcade)
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion for a total of 3 doses
Study: NCT00369226
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken until Doctor determines it is not necessary any more
Study: NCT00525733
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
Study: NCT00525733
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)
Study: NCT00525733
Drug: Ritonavir 100 mg
Normalized name: ritonavir 100 MG
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: one tablet of ritonavir is taken with darunavir daily
Study: NCT03873389
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients who are beginning this medication based on patient's treating physician's recommendation will be enrolled in the study.
Study: NCT00403533
Drug: 20 mg of atorvastatin daily
Normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no